Company intelligence / Profile preview

AuXin Surgery

Mont-Saint Guibert/Mont-Saint Guibert, Wallonie/Wallon Region/Région Wallonne, Belgiumx.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

The CADISS® System by AuXin Surgery enables selective chemical dissection during surgery by cleaving disulfide bonds that cause tissue adhesion or fibrosis. Clinical investigations have involved over 900 patients across at least eight different surgical procedures. The system aims to facilitate critical dissections while reducing the risk of damage to nerves, veins, or muscles. It has been commercially launched in several European countries.

Therapeutic areas: Other
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

University of Parma ENT surgeons team led by Prof. Carlo Zini contributed to invention/development.

Beyond the preview

Go deeper on AuXin Surgery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AuXin Surgery.

Explore the full profile